Abstract
Bisphosphonates have been widely used over the past decade to prevent skeletal complications in breast cancer patients with bone metastases. The skeletal complications associated with bone metastases include severe bone pain, pathologic fractures, spinal cord compression, and hypercalcemia. A number of bisphosphonates, including oral clodronate, intravenous (IV) pamidronate, IV zoledronic acid, and ibandronate have been shown to significantly reduce skeletal complications and palliate bone pain in patients with breast cancer based on placebo-controlled trials. However, only zoledronic acid and pamidronate have been directly compared within a single trial, and zoledronic acid (4 mg via 15- minute infusion) was shown to be significantly more effective than 90 mg pamidronate at reducing the overall risk of skeletal complications in patients with breast cancer. Both IV pamidronate and zoledronic acid are recommended by the American Society of Clinical Oncology for the treatment of malignant bone disease. As we look to the future, the role of bisphosphonates will continue to evolve beyond the prevention of skeletal complications. Encouraging results have recently been reported from studies assessing the effects of bisphosphonates on tumor progression in bone and for the prevention of cancer treatment-induced bone loss.
Keywords: breast cancer, skeletal complications, zoledronic acid, ibandronate, pamidronate, clodronate
Current Cancer Therapy Reviews
Title: Bisphosphonate Therapy for Patients with Breast Cancer
Volume: 1 Issue: 3
Author(s): Allan Lipton
Affiliation:
Keywords: breast cancer, skeletal complications, zoledronic acid, ibandronate, pamidronate, clodronate
Abstract: Bisphosphonates have been widely used over the past decade to prevent skeletal complications in breast cancer patients with bone metastases. The skeletal complications associated with bone metastases include severe bone pain, pathologic fractures, spinal cord compression, and hypercalcemia. A number of bisphosphonates, including oral clodronate, intravenous (IV) pamidronate, IV zoledronic acid, and ibandronate have been shown to significantly reduce skeletal complications and palliate bone pain in patients with breast cancer based on placebo-controlled trials. However, only zoledronic acid and pamidronate have been directly compared within a single trial, and zoledronic acid (4 mg via 15- minute infusion) was shown to be significantly more effective than 90 mg pamidronate at reducing the overall risk of skeletal complications in patients with breast cancer. Both IV pamidronate and zoledronic acid are recommended by the American Society of Clinical Oncology for the treatment of malignant bone disease. As we look to the future, the role of bisphosphonates will continue to evolve beyond the prevention of skeletal complications. Encouraging results have recently been reported from studies assessing the effects of bisphosphonates on tumor progression in bone and for the prevention of cancer treatment-induced bone loss.
Export Options
About this article
Cite this article as:
Lipton Allan, Bisphosphonate Therapy for Patients with Breast Cancer, Current Cancer Therapy Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339405774574261
DOI https://dx.doi.org/10.2174/157339405774574261 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Serotonergic Modulation of Spinal Sensory Circuits
Current Topics in Medicinal Chemistry Diagnostic Tools, Biomarkers, and Treatments in Diabetic polyneuropathy and Cardiovascular Autonomic Neuropathy
Current Diabetes Reviews Use of Telemetry Blood Pressure Transmitters to Measure Intracranial Pressure (ICP) in Freely Moving Rats
Current Neurovascular Research Plasmid DNA-based Gene Transfer with Ultrasound and Microbubbles
Current Gene Therapy Cell Elimination as a Strategy for Repair in Acute Spinal Cord Injury
Current Pharmaceutical Design The Role of MDCT in Craniocervical Junction Pathologies: Pictorial Review
Current Medical Imaging Inflammation: Beneficial or Detrimental After Spinal Cord Injury?
Recent Patents on CNS Drug Discovery (Discontinued) Assays for Eukaryotic Cell Chemotaxis
Combinatorial Chemistry & High Throughput Screening Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) L-Acetylcarnitine: A Proposed Therapeutic Agent for Painful Peripheral Neuropathies
Current Neuropharmacology Subject Index to Volume 10
Current Pharmaceutical Design Stem Cell Therapy for Spinal Cord Injury
Current Medicinal Chemistry Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Mechanisms and Treatment of Neuropathic Pain
Central Nervous System Agents in Medicinal Chemistry Effects of Melatonin on Ischemic Spinal Cord Injury Caused by Aortic Cross Clamping in Rabbits
Current Neurovascular Research Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design Post Traumatic Lesion absence of β-Dystroglycan-Immunopositivity in Brain Vessels Coincides with the Glial Reaction and the Immunoreactivity of Vascular Laminin
Current Neurovascular Research Boron Nitride Nanotubes: Production, Properties, Biological Interactions and Potential Applications as Therapeutic Agents in Brain Diseases
Current Nanoscience Perspectives on the Development of Antioxidant Antiepileptogenic Agents
Mini-Reviews in Medicinal Chemistry